JP2023518066A5 - - Google Patents

Info

Publication number
JP2023518066A5
JP2023518066A5 JP2022556091A JP2022556091A JP2023518066A5 JP 2023518066 A5 JP2023518066 A5 JP 2023518066A5 JP 2022556091 A JP2022556091 A JP 2022556091A JP 2022556091 A JP2022556091 A JP 2022556091A JP 2023518066 A5 JP2023518066 A5 JP 2023518066A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
concentration
arginine
histidine
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022556091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518066A (ja
JP7689141B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000155 external-priority patent/WO2021186245A1/en
Publication of JP2023518066A publication Critical patent/JP2023518066A/ja
Publication of JP2023518066A5 publication Critical patent/JP2023518066A5/ja
Priority to JP2025064827A priority Critical patent/JP2025111516A/ja
Application granted granted Critical
Publication of JP7689141B2 publication Critical patent/JP7689141B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022556091A 2020-03-20 2021-03-19 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法 Active JP7689141B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064827A JP2025111516A (ja) 2020-03-20 2025-04-10 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US62/992,746 2020-03-20
US202063027263P 2020-05-19 2020-05-19
US63/027,263 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064827A Division JP2025111516A (ja) 2020-03-20 2025-04-10 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2023518066A JP2023518066A (ja) 2023-04-27
JP2023518066A5 true JP2023518066A5 (cg-RX-API-DMAC7.html) 2024-10-08
JP7689141B2 JP7689141B2 (ja) 2025-06-05

Family

ID=75746958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556091A Active JP7689141B2 (ja) 2020-03-20 2021-03-19 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法
JP2025064827A Pending JP2025111516A (ja) 2020-03-20 2025-04-10 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064827A Pending JP2025111516A (ja) 2020-03-20 2025-04-10 高濃度抗Aβプロトフィブリル抗体製剤及びその使用方法

Country Status (28)

Country Link
US (1) US20230183328A1 (cg-RX-API-DMAC7.html)
EP (2) EP4252777B1 (cg-RX-API-DMAC7.html)
JP (2) JP7689141B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220156534A (cg-RX-API-DMAC7.html)
CN (1) CN115315251A (cg-RX-API-DMAC7.html)
AU (1) AU2021238951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174778A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002517A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012916A2 (cg-RX-API-DMAC7.html)
DK (1) DK4121007T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041762T3 (cg-RX-API-DMAC7.html)
FI (1) FI4121007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251087T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072937T2 (cg-RX-API-DMAC7.html)
IL (2) IL326613A (cg-RX-API-DMAC7.html)
LT (1) LT4121007T (cg-RX-API-DMAC7.html)
MA (1) MA59082B1 (cg-RX-API-DMAC7.html)
MD (1) MD4121007T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011101A (cg-RX-API-DMAC7.html)
PH (1) PH12022552172A1 (cg-RX-API-DMAC7.html)
PL (1) PL4121007T3 (cg-RX-API-DMAC7.html)
PT (1) PT4121007T (cg-RX-API-DMAC7.html)
RS (1) RS67249B1 (cg-RX-API-DMAC7.html)
SI (1) SI4121007T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500350T1 (cg-RX-API-DMAC7.html)
TW (1) TWI923576B (cg-RX-API-DMAC7.html)
WO (1) WO2021186245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
IL324807A (en) 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Similar Documents

Publication Publication Date Title
IL295383A (en) High concentration anti-aß protofibril antibody formulations and methods of use thereof
JP2024075713A5 (cg-RX-API-DMAC7.html)
JP2020518599A5 (cg-RX-API-DMAC7.html)
AR127344A2 (es) Conjugados anticuerpo-fármaco que comprenden agonistas de sting
JP2019506406A5 (cg-RX-API-DMAC7.html)
FI3644999T3 (fi) 2-(4-kloorifenyyli)-n-((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-5-yyli)metyyli)-2,2-difluoriasetamidin koostumukset ja menetelmät sen käyttämiseksi
JP2021519076A5 (cg-RX-API-DMAC7.html)
JP2013500947A5 (cg-RX-API-DMAC7.html)
JP2008515775A5 (cg-RX-API-DMAC7.html)
HRP20120893T1 (hr) Formulacija protutijela na histidin-acetatnom puferu
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
JP2012520882A5 (cg-RX-API-DMAC7.html)
JP2003525240A (ja) 糖尿病性腎障害の処置のためのpdgf受容体チロシンキナーゼ阻害剤の使用
JP2020532562A5 (cg-RX-API-DMAC7.html)
CN112166111A (zh) 治疗纤维化疾病的方法
RU2018129077A (ru) Стабильная фармацевтическая композиция
US20220296553A1 (en) Compositions for treating fungal and bacterial biofilms and methods of using the same
JP2024540395A5 (cg-RX-API-DMAC7.html)
EA200501129A1 (ru) Парентеральные композиции пептида для лечения системной красной волчанки
JP2023502398A5 (cg-RX-API-DMAC7.html)
IL276911B1 (en) Variants of the carboxylation rate of antibodies
JP2026016480A5 (cg-RX-API-DMAC7.html)
JP2022519796A5 (cg-RX-API-DMAC7.html)
JP2022501423A5 (cg-RX-API-DMAC7.html)
JP2025503251A5 (cg-RX-API-DMAC7.html)